Close
FINDING CURES TOGETHER<sup>SM</sup>

Advances in Pediatric Cancer Research

​Program 

Tuesday, Sept. 17, 2019

Wednesday, Sept. 18, 2019

Thursday, Sept. 19, 2019

Friday, Sept. 20, 2019 


Tuesday, Sept. 17, 2019

Opening Plenary Session
5-6 p.m.

Pediatric neuro-oncology: What's next?
Stefan Pfister, Hopp Children's Cancer Center at the NCT Heidelberg (KiTZ) and German Cancer Research Center, Heidelberg, Germany

Opening Reception
6-7:30 p.m.

Top of page


Wednesday, Sept. 18, 2019

Breakfast and Networking Roundtables
7-8 a.m.

Plenary Session 1: Cancer Predisposition and Surveillance
Session Chair: David Malkin, The Hospital for Sick Children, Toronto, Ontario, Canada
8-10 a.m.

Novel strategies for early cancer detection and prevention in pediatric cancer predisposition
David Malkin

Medulloblastoma predisposition according to molecular subgroup: The usual suspects and beyond
Paul A. Northcott, St. Jude Children’s Research Hospital, Memphis, Tennessee

Cancer predisposition and surveillance: New strategies
Christian P. Kratz, Hannover Medical School, Hannover, Germany

The potential of liquid biopsies: Clinical prognostication, tumor evolution, and early cancer detection
Brian Crompton, Boston Children’s Hospital, Boston, Massachusetts

Molecular characterisation of high risk pediatric cancer- confronting somatic and germline alterations
Gudrun Schleiermacher, Institut Curie, Paris, France


Break

10-10:30 a.m.


Plenary Session 2: Immunotherapy I – Cellular Therapies 
Session Chair: Crystal Mackall, Stanford University School of Medicine, Stanford, California
10:30 a.m.-12:30 p.m.

Next generation CAR T cells to overcome resistance
Crystal Mackall

Improving remission durability after CAR T cell therapy
Terry J. Fry, University of Colorado Denver, Aurora, Colorado

Immunotherapeutic approaches for pediatric solid tumors
Rupert Handgretinger, University of Tübingen, Tübingen, Germany


Lunch (on Own)
12:30-2:30 p.m.


Plenary Session 3: Immunotherapy II – Immune Checkpoint Inhibition and Tumor Microenvironment
Session Chair: Paul Sondel, University of Wisconsin School of Medicine, Madison, Wisconsin
2:30-4:30 p.m. 

Title to be announced
Paul Sondel

Overcoming immune evasion in pediatric brain tumors
Robert J. Wechsler-Reya, Sanford Burnham Prebys Medical Discovery Institute, La Jolla, California

Re-balancing the immune milieu in the early metastatic microenvironment
Rosandra N. Kaplan, National Cancer Institute, Bethesda, Maryland

2 short talks from proffered abstracts


Special Session: Poster Session A Highlights
4:30-4:45 p.m.
The goal of this session is to increase engagement and interaction during the poster sessions by highlighting the top research that will be presented as posters during the Poster Session A. 15 abstracts from Poster Session A will be featured in this speed presentation round. Presenters will have 1 minute to present 1 slide to highlight their most exciting finding which can then be discussed in greater depth during the poster sessions themselves. Abstracts chosen for regular proffered talks will not be selected for this session.


Poster Session A / Reception

4:45-7:15 p.m.

Top of page


Thursday, Sept. 19, 2019

Breakfast and Networking Roundtables
7-8 a.m.


Plenary Session 4: Molecularly Targeted Therapies
Session Chair: Gilles Vassal, Institut Gustave Roussy, Villejuif, France
8-10 a.m.

Molecular targeted therapies and precision medicine for children with neuroblastoma and other refractory malignancies
Michelle Haber, Children’s Cancer Institute, Randwick, New South Wales, Australia

Molecular profiling in the clinic: Moving from feasibility assessment to evaluating clinical impact
Katherine A. Janeway, Dana-Farber Cancer Institute, Boston, Massachusetts

Tissue agnostic development of TRK inhibitors for pediatric cancer
Theodore Laetsch, University of Texas Southwestern Medical Center, Dallas, Texas

Accelerating innovation for children with cancer in the new regulatory environment
Gilles Vassal


Break

10-10:30 a.m.


Plenary Session 5: Pathways of Oncogenesis I: ‘Omics
Session Chair: Kimberly Stegmaier, Dana-Farber Cancer Institute, Boston, Massachusetts
10:30 a.m.-12:30 p.m.

From functional genomics to new targets in pediatric oncology
Kimberly Stegmaier

Clinically relevant mutational signatures in childhood cancer
Adam Shlien, The Hospital for Sick Children, Toronto, Ontario, Canada

Genomic analysis of osteosarcoma: Insights in to tumor evolution and therapy response
E. Alejandro Sweet-Cordero, University of California, San Francisco, California

Developmental origins and microenvironmental drivers of pediatric glioma
Michelle L. Monje, Stanford University School of Medicine, Stanford, California


Special Session: Poster Session B Highlights
12:30-12:45 p.m.
The goal of this session is to increase engagement and interaction during the poster sessions by highlighting the top research that will be presented as posters during the Poster Session B. 15 abstracts from Poster Session B will be featured in this speed presentation round. Presenters will have 1 minute to present 1 slide to highlight their most exciting finding which can then be discussed in greater depth during the poster sessions themselves. Abstracts chosen for regular proffered talks will not be selected for this session.

Poster Session B / Lunch
12:45-3:15 p.m.


Plenary Session 6: Pathways of Oncogenesis II: Basic Biology
Session Chair: E. Alejandro Sweet-Cordero, University of California, San Francisco, California
3:15-5:15 p.m.

Metabolism of amino acids during carcinogenesis
Ayelet Erez, Weizmann Institute of Science, Rehovot, Israel

High-risk childhood sarcoma cells exploit diverse cellular mechanisms to reduce oxidative stress and increase metastatic capacity
Poul H.B. Sorensen, BC Cancer Research Centre, Vancouver, BC, Canada

Lessons from a rare childhood cancer syndrome on replication repair deficiency and hypermutation
Uri Tabori, The Hospital for Sick Children, Toronto, ON, Canada

Top of page


Friday, Sept. 20, 2019

Breakfast and Networking Roundtables
7-8 a.m.


Plenary Session 7: Survivorship Research
Session Chair: Gregory T. Armstrong, St. Jude Children’s Research Hospital, Memphis, Tennessee
8-10 a.m.

The lifetime impact of cancer and cancer therapy
Gregory T. Armstrong

Optimizing cancer survivorship outcomes with intervention, dissemination and implementation research
Tara O. Henderson, University of Chicago, Chicago, Illinois

The need for evidence-based survivorship care
Leontien C.M. Kremer, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands


Break

10-10:15 a.m.


Plenary Session 8: Tumor Heterogeneity
Session Chair: Sam Behjati, Wellcome Sanger Institute, Cambridge, United Kingdom
10:15-12:45 p.m.

Patient-derived organoids in pediatric cancer research
Jarno Drost, Princess Maxima Center for Pediatric Oncology, Utrecht, Netherlands

Tumor heterogeneity vs. transcriptional and embryological uniformity
Sam Behjat

Developmental and oncogenic programs in pediatric brain tumors dissected by single-cell RNA-sequencing
Mariella G. Filbin, Dana-Farber Cancer Institute, Boston, Massachusetts

Using single-cell, high-dimensional approaches to unravel tumor heterogeneity in pediatric cancer
Kara L. Davis, Stanford University School of Medicine, Stanford, California

Epigenome deregulation leads to stalled development in pediatric high-grade gliomas
Nada Jabado, McGill University, Montreal, Quebec, Canada


Closing Remarks
12:45-1 p.m. 


Top of page